We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
VIVUS Licenses Rights to PAH Drugs from Selten Pharma
Read MoreHide Full Article
VIVUS, Inc. acquired exclusive global rights to develop and commercialize pulmonary arterial hypertension (PAH) drugs, tacrolimus and ascomycin from private biotech company, Selten Pharma, Inc.
VIVUS’ share price has gained 24% in the past one year, while the Zacks classified Medical-Biomedical and Genetics industry fell 12.4%.
Selten also licensed a family of patents along with all rights under a collection of patent applications to VIVUS. The licensed patent family includes a patent (‘745) that deals with methods of using tacrolimus to treat PAH. The assigned patent applications are directed to additional compounds and methods for the treatment of PAH and formulations for tacrolimus. In Mar 2015, Selten received orphan drug designation for tacrolimus for the treatment of PAH.
VIVUS assumes all development and commercialization responsibilities. Meanwhile, Selten will receive an upfront payment, and development and sales milestone payments, along with tiered royalties on future sales of these compounds.
PAH is a chronic life-threatening disease characterized by increased blood pressure in the pulmonary arteries. The disease currently has treatment options that only to slow down the advancement of the disease. Thus, the collaboration between the two companies is an effort to bring new therapies for the PAH market.
The PAH market is already crowded with drugs like Adcirca, Revatio, United Therapeutics Corporation’s (UTHR - Free Report) Tyvaso and Actelion Ltd.’s Veletri, among others.
Meanwhile, several other companies are also looking to bring their own PAH treatments to the market. Arena Pharmaceuticals, Inc. is currently evaluating its PAH candidate, ralinepag, in a phase II study. Results from the study are expected in mid 2017. Ralinepag enjoys Orphan Drug status in the U.S.
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? As of early December, the 2016 Top 10 produced 5 double-digit winners including oil and natural gas giant Pioneer Natural Resources which racked up a stellar +50% gain. The new list is painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. Be among the very first to see it>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
VIVUS Licenses Rights to PAH Drugs from Selten Pharma
VIVUS, Inc. acquired exclusive global rights to develop and commercialize pulmonary arterial hypertension (PAH) drugs, tacrolimus and ascomycin from private biotech company, Selten Pharma, Inc.
VIVUS’ share price has gained 24% in the past one year, while the Zacks classified Medical-Biomedical and Genetics industry fell 12.4%.
Selten also licensed a family of patents along with all rights under a collection of patent applications to VIVUS. The licensed patent family includes a patent (‘745) that deals with methods of using tacrolimus to treat PAH. The assigned patent applications are directed to additional compounds and methods for the treatment of PAH and formulations for tacrolimus. In Mar 2015, Selten received orphan drug designation for tacrolimus for the treatment of PAH.
VIVUS assumes all development and commercialization responsibilities. Meanwhile, Selten will receive an upfront payment, and development and sales milestone payments, along with tiered royalties on future sales of these compounds.
PAH is a chronic life-threatening disease characterized by increased blood pressure in the pulmonary arteries. The disease currently has treatment options that only to slow down the advancement of the disease. Thus, the collaboration between the two companies is an effort to bring new therapies for the PAH market.
The PAH market is already crowded with drugs like Adcirca, Revatio, United Therapeutics Corporation’s (UTHR - Free Report) Tyvaso and Actelion Ltd.’s Veletri, among others.
Meanwhile, several other companies are also looking to bring their own PAH treatments to the market. Arena Pharmaceuticals, Inc. is currently evaluating its PAH candidate, ralinepag, in a phase II study. Results from the study are expected in mid 2017. Ralinepag enjoys Orphan Drug status in the U.S.
Zacks Rank
VIVUS currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
VIVUS, Inc. Price
VIVUS, Inc. Price | VIVUS, Inc. Quote
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? As of early December, the 2016 Top 10 produced 5 double-digit winners including oil and natural gas giant Pioneer Natural Resources which racked up a stellar +50% gain. The new list is painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. Be among the very first to see it>>